Arq Publishes its First-Ever ESG Report
September 25, 2024 08:15 ET
|
Arq, Inc.
GREENWOOD VILLAGE, Colo., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Arq, Inc. (NASDAQ: ARQ) (the "Company" or "Arq"), a producer of activated carbon and other environmentally efficient carbon products,...
NEWTON GOLF Introduces New Gravity Putter Line, Building on Momentum from Recent Rebranding
September 25, 2024 08:15 ET
|
Sacks Parente Golf, Inc.
Gravity, the putter division of parent company NEWTON GOLF, introduces five putters in its new premium series CAMARILLO, CA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- NEWTON GOLF, (Nasdaq: SPGC)...
FinWise Bancorp Announces Strategic Lending Program with PowerPay to Offer Transparent and Affordable Monthly Payments for Home Improvement and Elective Healthcare Purchases
September 25, 2024 08:15 ET
|
FinWise Bank
MURRAY, Utah, Sept. 25, 2024 (GLOBE NEWSWIRE) -- FinWise Bancorp (NASDAQ: FINW) (“FinWise” or the “Company”), parent company of FinWise Bank (the “Bank”), today announced the launch of a new...
Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
September 25, 2024 08:15 ET
|
Windtree Therapeutics
Istaroxime significantly improved primary endpoint of the systolic blood pressure profile over six hours and showed significant improvements in many secondary endpoint assessments Study results to be...
CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology
September 25, 2024 08:00 ET
|
Centogene NV
Rostock International Parkinson's Disease (ROPAD) Study demonstrates a significant link between the RAB32 gene variant and Parkinson's disease, further supporting recent findingsData from over...
Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension in Improving Narcolepsy Symptoms Regardless of Concomitant Use of an Alerting Agent
September 25, 2024 08:00 ET
|
Avadel Pharmaceuticals plc
– Post-hoc analysis from pivotal Phase 3 REST-ON trial confirmed the efficacy of LUMRYZ in study participants who were and were not using a stable dose of an alerting agent – – Baseline data...
Tactile Medical Announces Positive Clinical Trial Results in Lymphedema Patients Using Advanced Pneumatic Compression Device Therapy
September 25, 2024 08:00 ET
|
Tactile Systems Technology, Inc.
MINNEAPOLIS, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with...
NV5 Announces 4-for-1 Stock Split; Enhances Accessibility of Stock Ownership for Employees and Investors
September 25, 2024 08:00 ET
|
NV5 Global, Inc.
HOLLYWOOD, Fla., Sept. 25, 2024 (GLOBE NEWSWIRE) -- NV5 Global, Inc. (the “Company” or “NV5”) (Nasdaq: NVEE), a provider of technology, certification, and consulting solutions, announced that it...
Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension
September 25, 2024 08:00 ET
|
Mineralys Therapeutics, Inc.
– On track to announce topline data in Q1 2025 – – Virtual KOL event scheduled on October 30th to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program...
Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference
September 25, 2024 08:00 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...